title: Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital.
abstract: OBJECTIVE
  The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia.
  
  
  METHODS
  A retrospective review was performed of 100 non-electronic records of patients with Ph(+) chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package.
  
  
  RESULTS
  At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response.
  
  
  CONCLUSIONS
  The population of this study obtained lower-than-expected therapeutic responses compared to other studies.
authors.affiliation: Universidade Federal do Ceará, UFC, Fortaleza, CE, Brazil.
authors.forename: Samuel Roosevelt Campos
authors.initials: SR
authors.lastname: Dos Reis
authors.forename: Acy Telles de Souza
authors.initials: AT
authors.lastname: Quixadá
authors.forename: Sammara Tavares
authors.initials: ST
authors.lastname: Nunes
authors.forename: Danielle Maria Camelo
authors.initials: DM
authors.lastname: Cid
authors.forename: Jacqueline Holanda
authors.initials: JH
authors.lastname: de Souza
authors.forename: Clara Maria Bastos Eloy
authors.initials: CM
authors.lastname: da Costa
authors.forename: Carolina Bizelli
authors.initials: CB
authors.lastname: Silveira
authors.forename: David Antonio Camelo
authors.initials: DA
authors.lastname: Cid
authors.forename: Mariana Fátima Cabral
authors.initials: MF
authors.lastname: de Oliveira
keywords: Fusion Proteins, bcr-abl/genetic; Treatment outcome; Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy; Medication adherence; Piperazines/therapeutic use
references.citation: Curr Oncol Rep. 2010 Jul;12(4):247-52
references.pmid: 20437116
references.citation: Curr Hematol Malig Rep. 2010 Apr;5(2):70-80
references.pmid: 20425399
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references.pmid: 18519952
references.citation: Pharmacoeconomics. 2007;25(6):481-96
references.pmid: 17523753
references.citation: Clin Adv Hematol Oncol. 2009 Nov;7(11):763-7
references.pmid: 20075835
references.citation: Leuk Res. 2011 May;35(5):626-30
references.pmid: 21095002
references.citation: Leukemia. 2009 Sep;23(9):1537-44
references.pmid: 19404318
references.citation: Blood. 2011 Apr 7;117(14):3733-6
references.pmid: 21346253
references.citation: CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66
references.pmid: 19147869
references.citation: J Clin Oncol. 2010 May 10;28(14):2381-8
references.pmid: 20385986
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: Int J Hematol. 2010 Jun;91(5):897-902
references.pmid: 20437122
references.citation: Am J Hematol. 2011 Jun;86(6):471-4
references.pmid: 21538468
references.citation: Eur J Clin Pharmacol. 2009 Jun;65(6):545-9
references.pmid: 19214491
references.citation: Value Health. 2007 Jan-Feb;10(1):3-12
references.pmid: 17261111
references.citation: J Clin Oncol. 2003 Apr 15;21(8):1637-47
references.pmid: 12668652
references.citation: Blood. 2008 Apr 15;111(8):4022-8
references.pmid: 18256322
references.citation: Blood. 2009 May 28;113(22):5401-11
references.pmid: 19349618
references.citation: Value Health. 2008 Jan-Feb;11(1):44-7
references.pmid: 18237359